CARM
Carisma Therapeutics, Inc.NASDAQHealthcare$0.03+0.29%ClosedMarket Cap: $1.4M
As of 2026-04-07
Valuation
P/E (TTM)
0.18
PEG
0.00
P/B
-1.63
P/S
0.03
EV/EBITDA
-0.04
DCF Value
$-13.90
FCF Yield
-1580.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.1%
Operating Margin
20.6%
Net Margin
15.3%
ROE
-28.9%
ROA
122.7%
ROIC
-10330.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $45.3M | 100.0% | $43.8M | $44.7M | $1.07 | — |
| Q2 2025 | $0.00 | -Infinity% | $-5.8M | $-9.8M | $-0.23 | — |
| Q1 2025 | $3.7M | 100.0% | $-9.3M | $-9.3M | $-0.22 | — |
| Q4 2024 | $3.7M | 81.7% | $-17.9M | $-17.6M | $-0.42 | — |
| FY 2024 | $19.6M | -204.0% | $-62.2M | $-60.5M | $-1.46 | — |
| Q3 2024 | $3.4M | 100.0% | $-13.1M | $-12.7M | $-0.31 | — |
| Q2 2024 | $9.2M | -66.4% | $-11.7M | $-11.2M | $-0.27 | — |
| Q1 2024 | $3.4M | -414.0% | $-19.5M | $-19.0M | $-0.46 | — |
| Q4 2023 | $4.3M | 51.4% | $-22.4M | $-21.0M | $-0.52 | — |
| FY 2023 | $14.9M | -396.8% | $-88.7M | $-86.9M | $-2.59 | $0.36 |
| Q3 2023 | $3.8M | -410.9% | $-22.3M | $-21.4M | $-0.53 | — |
| Q2 2023 | $3.6M | -420.2% | $-21.0M | $-19.9M | $-0.49 | — |